Opinion|Videos|August 2, 2024
Sequencing Second-Line Treatments for LR-MDS
Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions.
Advertisement
Episodes in this series
- Let’s explore sequencing strategies for lower-risk MDS in the 2L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
- Dr Komrokji: How do you approach treating patients with luspatercept from based on data from the MEDALIST trial? (
Santini V, et al. ASH 2023. Abstract 915 )- What is the impact of fatigue events on overall treatment outcomes in patients treated with luspatercept for LR-MDS?
- Dr. Thomas Cluzeau: Based on the results from the MEDALIST trial, how would you approach dose escalation for 2L treatment of luspatercept in patients with LR-MDS? (
Platzbecker U et al. Blood 2022 )
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5